EBF3 and colorectal cancer: In the metastatic colon cancer tumour sample, there was a clear increase in methylation (~ 20%) in the EBF3 promoter compared to the primary colon cancer tumour sample, and a corresponding decrease in methylation (~ 20%) at most sites within the EBF3 gene body in the metastatic vs primary colorectal cancer samples.